Treos Bio

About

Treos Bio, Inc. develops precision cancer immunotherapies tailored to patients' genetics.

London,England,United Kingdom
1 - 10

Highlights

Details

Last Funding Type: Series Unknown
Last Funding Money Raised: $8M
Industries: Biotechnology,Clinical Trials,Health Care,Health Diagnostics,Therapeutics
Founded date: Jan 1, 2013
Number Of Employee: 1 - 10
Operating Status: Active

Treos Bio, Inc. is a computational immunology and immunotherapy company which has developed a proprietary technology to predict in silico likely responders to cancer immunotherapies and to design in silico next generation targeted immunotherapies for a large population of cancer patients.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

$8M €25.67M

Treos Bio has raised a total of $8M €25.67M in funding over 2 rounds. Their latest funding was raised on Mar 31, 2021 from a Convertable Note round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Mar 31, 2021	Convertable Note	€14M	2	Luminous Ventures The Future Fund	—	Detail
Mar 20, 2021	Series A	€11.67M	1	—	—	Detail
Feb 13, 2017	Series Unknown	$8M	1	BXR Partners LLP	—	Detail